Actions of the novel gastrointestinal pro kinetic agent cisapride on equine bowel motility

Abstract

The effect of cisapride was evaluated on the normal fasting bowel motility of four ponies with chronically implanted electromechanical transducers. Cisapride was infused over 60-min periods at 0.05 mg/kg (n = 4), 0.1 mg/kg (n = 5) and 0.25 mg/kg (n = 5). It produced marked and prolonged increases in electrical and mechanical activity at all sites examined. In the stomach there was increased total contraction activity with increased contraction amplitude and a slight reduction in rate. In the small intestine there was an increase in irregular (phase II) activity with an increase in number and amplitude of contractions and a decrease in the number of regular (phase III) activity fronts. There was a decrease in the number of phase III fronts that spread distally from the jejunum to the ileum. The phase II activity was coordinated temporally with prolonged activity in the stomach. Cisapride increased electrical and contractile activity in the left dorsal colon with increased contraction amplitude and an increase in electrical activity in the small colon. In the stomach and small intestine cisapride produced dose-dependent increases in activity but in the left dorsal and small colon the intermediate dose (0.1 mg/kg) produced the largest and most consistent responses. Side-effects observed were increased bowel sounds and frequency of defaecation, a slight increase in heart rate and transient signs of discomfort at the highest (0.25 mg/kg) dose rate.

In vitroeffects of cisapride, metoclopramide and bethanechol on smooth muscle preparations from abomasal antrum and duodenum of dairy cows

“…, 2000a). In vivo , CIS produced an increase in myoelectric activity of the stomach and small intestine (King & Gerring, 1988), as well as of the caecal body and caecal base. In cattle, CIS (7.5 × 10 −5 m ) did not have any effect on longitudinal smooth muscle preparations from the proximal colon in vitro (Steiner et al.…”

A controlled trial of cisapride in anorexia nervosa

“…Prolonged transit times have been reported in anorexia nervosa (Kamal et al, 1991) and it is possible that changes in bowel activity may be perceptible by patients with such abnormalities. Cisapride may also alter gastric myoelectric activity (King & Gerring, 1988) and myoelectric abnormalities are observed in patients with gastric symptoms but normal emptying (Koch, Medina, Bingaman, & Stern, 1992).…”

Motility of the equine gastrointestinal tract: Physiology and pharmacotherapy

“…2000a). Cisapride has no anti‐dopaminergic properties and thus is devoid of the extrapyramidal side effects associated with metoclopramide (King and Gerring 1988; Nieto et al . 2000a).…”